News - Kyowa Hakko Kirin, Debiopharm

Filter

Popular Filters

1 to 25 of 37 results

Debiopharm to acquire products or companies to expand activities at Swiss manufacturing facility

06-03-2014

Swiss independent drug developer Debiopharm say it plans to expand and optimize activities at Debiopharm…

DebiopharmMergers & AcquisitionsPharmaceuticalProduction

Debiopharm to acquire Affinium's antibiotic clinical assets and platform

11-02-2014

Swiss drug developer Debiopharm Group has entered into an agreement to acquire Canadian venture capital…

Affinium PharmaceuticalsAFN-1720Antibiotics and Infectious diseasesDebiopharmMergers & AcquisitionsPharmaceutical

Kyowa Hakko drops Ph II study of bardoxolone

11-11-2013

Japanese drugmaker Kyowa Hakko Kirin says it is discontinuing its Phase II clinical studies evaluating…

DiabetesKyowa Hakko KirinNephrology and HepatologyPharmaceuticalReata PharmaceuticalsResearch

AstraZeneca advances Medimmune’s benralizumab to Phase III in severe asthma

AstraZeneca advances Medimmune’s benralizumab to Phase III in severe asthma

30-10-2013

AstraZeneca has started the Phase III Windward program for benralizumab, a potential treatment for severe…

AstraZenecaEuropeKyowa Hakko KirinMedImmunePharmaceuticalResearchRespiratory and Pulmonary

Debiopharm collaborates with A*STAR’s ETC on oncology targets

07-10-2013

Swiss independent drug developer Debiopharm has signed an exclusive research collaboration with the Singapore-based…

A*STARAsia-PacificDebiopharmOncologyPharmaceuticalResearch

ProStrakan initiates EU launch of Sancuso

30-09-2013

ProStrakan has started the European Union roll-out of its transdermal patch Sancuso for the prevention…

BiotechnologyEuropeKyowa Hakko KirinLicensingOncologyProStrakanSancuso

Kyowa Hakko establishes translation research lab in Singapore

10-09-2013

Japanese mid-sized drugmaker Kyowa Hakko Kirin (TYO: 41521) has established an international R&D center…

Asia-PacificKyowa Hakko KirinPharmaceuticalResearch

Kyowa Hakko Kirin collaborates with Ultragenyx on KRN23

06-09-2013

Japanese mid-sized drugmaker Kyowa Hakko Kirin (TYO: 4151) has entered into a collaboration and license…

BiotechnologyKRN23Kyowa Hakko KirinLicensingPharmaceuticalRare diseasesResearchUltragenyx

Japan briefs: Kyowa Kirin debuts Onglyza; Otsuka enrolls TB study, sets up new European

10-07-2013

Japanese drugmaker Kyowa Hakko Kirin (TY: 4151) revealed that it launched the type 2 diabetes drug Onglyza…

Asia-PacificdelamanidEuropeKyowa Hakko KirinMarkets & MarketingOnglyzaOtsukaPharmaceuticalResearch

Kyowa Hakko launches PD drug Nouriast and files for additional indication of fluorouracil in Japan

31-05-2013

Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) say that it launched its novel Parkinson's disease drug…

Asia-PacificfluorouracilKyowa Hakko KirinMarkets & MarketingNeurologicalNouriastOncologyPharmaceuticalRegulation

Shasun and Debiopharm ink deal for Huperzine-A

10-04-2013

Swiss independent drug developer Debiopharm has entered into an accord with India-based contract manufacturer…

DebiopharmHuperzine-ALicensingNeurologicalPharmaceuticalProductionShasun Pharmaceuticals

Kyowa Hakko set to file for pegfilgrastim approval in Japan following strong Ph III data

28-01-2013

Mid-size Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) on Friday released positive top-line results…

Asia-PacificBiotechnologyKyowa Hakko KirinOncologypegfilgrastimPharmaceuticalRegulationResearch

Drug discovery alliances for Boehringer and Horizon Discovery; and NovAliX with Kyowa Hakko

15-01-2013

UK-based Horizon Discovery, a provider of research tools to support the development of personalized medicines,…

Boehringer IngelheimHorizon DiscoveryKyowa Hakko KirinLicensingNovAliXOncologyPharmaceuticalResearch

Dr Reddy's launches Debiopharm's cancer drug Pamorelin LA in India

09-12-2012

Independent Swiss biopharma firm Debiopharm Group announced on Friday that, on December 3, Dr. Reddy's…

Asia-PacificDebiopharmDr Reddy's LaboratoriesLicensingMarkets & MarketingOncologyPamorelinPharmaceutical

Kyowa Hakko files for additional indications for Leunase

08-10-2012

Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) says that it has filed an application based on evidence…

Asia-PacificKyowa Hakko KirinLeunaseOncologyPharmaceuticalRegulation

ProStrakan buys GTx' US rights to breast cancer drug Fareston

02-10-2012

Scotland-based ProStrakan, a subsidiary of Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151), has acquired…

FarestonGTxKyowa Hakko KirinMarkets & MarketingOncologyOrion PharmaPharmaceuticalProStrakan

Kyowa Hakko Kirin returns rights to Busulfex to Otsuka

17-09-2012

Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) has reached agreement on returning development and marketing…

BusulfexKyowa Hakko KirinLicensingOncologyOtsukaPharmaceutical

1 to 25 of 37 results

Back to top